Anti-HER2 Antibody Formulation Stability via Buffer and Surfactant Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations for anti-HER2 antibodies lack stability, particularly in liquid form, which is essential for both lyophilized and reconstituted formulations, affecting their efficacy and shelf life.
Innovation Solution
A pharmaceutical formulation comprising an anti-HER2 antibody with a heavy chain of SEQ ID NO: 10 and a light chain of SEQ ID NO: 11, combined with an acetate buffer, Polysorbate 80 as a surfactant, sucrose or mannitol as lyoprotectants, and glycine as a bulking agent, maintaining a pH of 5.0-6.0, to enhance stability and prevent aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If conventional formulations are used for anti-HER2 antibodies, then the formulation can be prepared, but the physical and chemical stability of the antibody deteriorates during storage
Solution Approach 1:
The patent optimizes specific formulation parameters including buffer type (acetate or citrate at pH 5.0-6.0), surfactant concentration (Polysorbate 20 or 80 at 0.001-0.1%), and lyoprotectant ratios (sucrose and mannitol in specific combinations) to achieve enhanced stability. These parameter optimizations prevent antibody aggregation and degradation during storage, directly resolving the stability-shelf life contradiction
Solution Approach 2:
The formulation uses a composite approach by combining multiple excipients (buffers, surfactants, lyoprotectants) in specific ratios rather than relying on a single stabilizing agent. This composite formulation strategy synergistically enhances both physical and chemical stability while extending shelf life, addressing the technical contradiction through material composition optimization
2Ease of operation
If the antibody is formulated in liquid form for ease of use, then ease of operation improves, but aggregation and instability increase
Solution Approach 1:
The patent introduces surfactants (Polysorbate 20 or 80) as intermediary substances that mediate between the antibody and the aqueous environment. These surfactants adsorb at interfaces and prevent protein aggregation by reducing surface tension and preventing protein-protein interactions, thereby maintaining liquid formulation stability while preserving ease of use
Solution Approach 2:
The formulation incorporates lyoprotectants (sucrose and mannitol) that provide beforehand protection against aggregation. These molecules form a protective matrix around the antibody in the liquid state and become particularly effective during freeze-drying and reconstitution, preventing aggregation before it can occur and maintaining ease of operation
3Ease of operation
If the antibody undergoes freeze-thaw cycles for storage convenience, then ease of operation improves, but physical integrity deteriorates
Solution Approach 1:
The lyoprotectants (sucrose and mannitol) are incorporated beforehand into the formulation to cushion against the mechanical and osmotic stresses of freeze-thaw cycles. These molecules prevent ice crystal formation that would otherwise damage the antibody structure, and maintain molecular spacing during phase transitions, thereby preserving physical integrity while enabling convenient frozen storage
Solution Approach 2:
The formulation is specifically designed to manage phase transitions during freeze-thaw cycles. The buffer system maintains pH stability during freezing and thawing, while the lyoprotectants control the phase behavior of water and prevent denaturation during the liquid-solid transitions, protecting physical integrity through controlled phase change management
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation significantly improves the physical and chemical stability of anti-HER2 antibodies, maintaining their integrity and biological activity during storage, whether at room temperature, elevated temperatures, or after freeze-thaw cycles, making them suitable for extended use.
Implementation Method 1
an acetate buffer, wherein the acetate buffer is sodium acetate buffer present within the pharmaceutical formulation in an amount of between 1 and 10mM
Implementation Method 2
a surfactant, wherein the surfactant is Polysorbate 80, present within said pharmaceutical formulation in an amount of between 0.001% and 0.1% (w/w)
Implementation Method 3
a lyoprotectant, wherein the lyoprotectant is sucrose present within the pharmaceutical formulation in an amount of between 5% and 15% (w/w) or sucrose and mannitol present within the pharmaceutical formulation in an amount of 5% and 15% (w/w) and between 0.5% and 5% (w/w)
Implementation Method 4
a bulking agent, wherein the bulking agent is glycine present within the pharmaceutical formulation in an amount of between 0.5% and 1.5% (w/w)
Data Source
Figure 1a~1b
Figure 1c~1d
Figure 2a
AI summary
A pharmaceutical formulation is described comprising a therapeutically effective amount of an antibody, an acetate buffer, a lyoprotectant, a bulking agent and a surfactant.